Brought to you by 
Curis and Wyeth end hedgehog pathway deal for neurology
13 Mar 2008
Executive Summary
Regenerative medicine company Curis has licensed Wyeth Pharmaceuticals its preclinical Hedgehog proteins and small-molecule Hedgehog pathway agonists for the development of neurological disorder therapeutics.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Curis and Wyeth end hedgehog pathway deal for neurology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice